Maria Luisa Alamillo
Research Subjects
Maria Luisa Alamillo has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Belén Pimentel
Medical Department, BioPharmaceuticals, AstraZeneca, 28046 Madrid, Spain
2 shared publications - José Carlos Fernández-García
Department of Endocrinology and Nutrition, Regional University Hospital of Málaga, Biomedical Research Institute of Málaga and Nanomedicine Platform (IBIMA-Plataforma BIONAND), 29010 Málaga, Spain
2 shared publications - José Ignacio Martínez-Montoro
Department of Endocrinology and Nutrition, Virgen de la Victoria University Hospital, 29010 Málaga, Spain
2 shared publications - José Juan Aparicio Sánchez
Medical Department, BioPharmaceuticals, AstraZeneca, 28046 Madrid, Spain
2 shared publications - Mónica Juárez-Campo
Medical Department, BioPharmaceuticals, AstraZeneca, Madrid, Spain
1 shared publication - Mónica Juárez-Campo
Medical Department, BioPharmaceuticals, AstraZeneca, 28046 Madrid, Spain
1 shared publication
Latest Publications
- Open Access
- 21 August 2026
- Published by MDPI AG in Medical Sciences
- Vol. 14 (4) , 506
Five-Year Cardiorenal Outcomes and Longitudinal Chronic Kidney Disease Screening in People with Type 2 Diabetes Managed by Endocrinologists: A Nationwide Retrospective Cohort Study
Background/Objectives: Type 2 diabetes (T2D) is a major risk factor for cardiovascular disease and chronic kidney disease (CKD), yet the extent of longitudinal CKD screening in routine clinical practice remains unclear. This study aimed to assess long-term cardiorenal outcomes and CKD screening practices in patients with T2D managed across primary care and endocrinology settings, evaluating the feasibility of risk stratification in real-world practice. Methods: We conducted a retrospective cohort study using anonymized data from the Telotrón database (2.2 million patients). Adults with T2D attended across primary and endocrinology care were followed from 1 January 2018 to 31 December 2022. Frequency of estimated glomerular filtration rate (eGFR) and urine albumin-to-creatinine ratio (UACR) measurements, and cumulative proportion of kidney and cardiovascular events, hospitalizations, and mortality were assessed. Results: Among 13,600 individuals, 31.1% experienced a kidney event and 18.6% a cardiovascular event over 5 years. All-cause hospitalization occurred in 24.9% and 16.1% died. First occurrence of an abnormal eGFR or UACR measurement occurred in 37.0% of participants without baseline CKD, and 45.4% with baseline CKD showed progression. Annual monitoring was limited, with 39.1% and 16.6% undergoing at least one yearly assessment, and 2.9 and 1.5 mean number of measurements per patient for eGFR and UACR, respectively. Conclusions: Despite receiving endocrinology care, kidney disease progression and cardiovascular events remain a major concern in T2D, and yet suboptimal albuminuria and eGFR assessment limit early detection and risk stratification, thereby hindering risk-directed management.
- 21 August 2026
- Published by MDPI AG in Medical Sciences
- Vol. 14 (4) , 506
Open AccessFive-Year Cardiorenal Outcomes and Longitudinal Chronic Kidney Disease Screening in People with Type 2 Diabetes Managed by Endocrinologists: A Nationwide Retrospective Cohort Study
Background/Objectives: Type 2 diabetes (T2D) is a major risk factor for cardiovascular disease and chronic kidney disease (CKD), yet the extent of longitudinal CKD screening in routine clinical practice remains unclear. This study aimed to assess long-term cardiorenal outcomes and CKD screening practices in patients with T2D managed across primary care and endocrinology settings, evaluating the feasibility of risk stratification in real-world practice. Methods: We conducted a retrospective cohort study using anonymized data from the Telotrón database (2.2 million patients). Adults with T2D attended across primary and endocrinology care were followed from 1 January 2018 to 31 December 2022. Frequency of estimated glomerular filtration rate (eGFR) and urine albumin-to-creatinine ratio (UACR) measurements, and cumulative proportion of kidney and cardiovascular events, hospitalizations, and mortality were assessed. Results: Among 13,600 individuals, 31.1% experienced a kidney event and 18.6% a cardiovascular event over 5 years. All-cause hospitalization occurred in 24.9% and 16.1% died. First occurrence of an abnormal eGFR or UACR measurement occurred in 37.0% of participants without baseline CKD, and 45.4% with baseline CKD showed progression. Annual monitoring was limited, with 39.1% and 16.6% undergoing at least one yearly assessment, and 2.9 and 1.5 mean number of measurements per patient for eGFR and UACR, respectively. Conclusions: Despite receiving endocrinology care, kidney disease progression and cardiovascular events remain a major concern in T2D, and yet suboptimal albuminuria and eGFR assessment limit early detection and risk stratification, thereby hindering risk-directed management.
- Open Access
- 19 June 2025
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 226, 112326
Screening, prevalence, and burden of chronic kidney disease in people with type 2 diabetes managed by endocrinologists: A nationwide cross-sectional study
- 19 June 2025
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 226, 112326
Open AccessScreening, prevalence, and burden of chronic kidney disease in people with type 2 diabetes managed by endocrinologists: A nationwide cross-sectional study